AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
Amgen · Project update · November 11, 2026
Amgen shared positive results from its Phase 3 clinical trial evaluating dazodalibep for the treatment of Sjögren's disease. The study met its primary endpoints, demonstrating the potential of the therapeutic candidate.
AntSpace’s summary of Amgen’s own announcement: read the original.